Literature DB >> 7475058

Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance.

M M Adamantidis1, D L Lacroix, J F Caron, B A Dupuis.   

Abstract

Astemizole is a potent histamine H1-antagonist that has been associated with cases of life-threatening cardiac arrhythmias, including torsade de pointes and atrioventricular (AV) block. However, its effects on cardiac action potential (AP) has not been described. We examined the electrophysiological effects of astemizole on rabbit Purkinje fibers using conventional glass microelectrodes in parallel with the effects of the widely used histamine H2-antagonist cimetidine, selected because it has no known cardiac arrhythmic toxicity. Astemizole (0.01-3 microM) exerted a concentration-dependent prolonging effect on final repolarization that did not reach steady state after 3 h of exposure. This effect was more pronounced at low stimulation frequency and was less marked at high stimulation frequency. In addition, early afterdepolarizations (EADs) occurred in one third of the fibers. Increasing extracellular concentration of KCl (2.7-5.4 mM) or MgCl2 (1-5 mM) suppressed EADs and reversed the prolonging effect that was conversely exaggerated by decreasing KCl (4-2.7 mM) or MgCl2 (1-0.5 mM) concentration. At higher concentrations (3-30 microM), astemizole induced an increasing depressant effect on the maximal rate of depolarization (Vmax) that became more pronounced with high stimulation frequency. All parameters were strongly depressed at 10 microM astemizole, leading to cellular inexcitability in 5 of 12 fibers when exposed to 30 microM astemizole. In comparison, cimetidine induced minor changes on AP characteristics, i.e., a prolongation in plateau duration at high (30-100 microM) concentrations. These results provide evidence that astemizole exerts quinidine-like effects on cardiac APs that are compatible with the occurrence of the clinically observed arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475058     DOI: 10.1097/00005344-199508000-00019

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 2.  Blockade of cardiac potassium and other channels by antihistamines.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 3.  Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

Authors:  I Cavero; M Mestre; J M Guillon; E Heuillet; A G Roach
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

4.  Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites.

Authors:  Hua Rong Lu; Haoyu Zeng; Ralf Kettenhofen; Liang Guo; Ivan Kopljar; Karel van Ammel; Fetene Tekle; Ard Teisman; Jin Zhai; Holly Clouse; Jennifer Pierson; Michael Furniss; Armando Lagrutta; Frederick Sannajust; David J Gallacher
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

5.  Repolarizing K+ currents in rabbit heart Purkinje cells.

Authors:  J M Cordeiro; K W Spitzer; W R Giles
Journal:  J Physiol       Date:  1998-05-01       Impact factor: 5.182

6.  Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.

Authors:  F L Puisieux; M M Adamantidis; B M Dumotier; B A Dupuis
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.